Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment D. Butov (Kharkiv, Ukraine), Y. Feshchenko (Kiev, Ukraine), M. Kuzhko (Kiev, Ukraine), M. Gumenuik (Kiev, Ukraine), Y. Kateryna (Kharkiv, Ukraine), A. Tkachenko (Kharkiv, Ukraine), N. Nekrasova (Kharkiv, Ukraine), N. Gulchuk (Kiev, Ukraine), T. Tlustova (Kiev, Ukraine), T. Butova (Kharkiv, Ukraine)
Source: International Congress 2019 – Tuberculosis: treatment and management
Session: Tuberculosis: treatment and management Session type: Poster DiscussionNumber: 5272
Disease area: Respiratory infectionsRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Butov (Kharkiv, Ukraine), Y. Feshchenko (Kiev, Ukraine), M. Kuzhko (Kiev, Ukraine), M. Gumenuik (Kiev, Ukraine), Y. Kateryna (Kharkiv, Ukraine), A. Tkachenko (Kharkiv, Ukraine), N. Nekrasova (Kharkiv, Ukraine), N. Gulchuk (Kiev, Ukraine), T. Tlustova (Kiev, Ukraine), T. Butova (Kharkiv, Ukraine). Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment. 5272
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
The choice of 4th drug in treatment of cavitary smear positive pulmonary tuberculosis: streptomycine versus ethambutol Source: Eur Respir J 2005; 26: Suppl. 49, 645s Year: 2005
Response to empirical anti-tuberculosis treatment in patients with sputum smear-negative pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 845s Year: 2006
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Treatment results of cases of severe pulmonary tuberculosis with using rifabutin Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Rifampicin and INH monoresistance prevalence among Iraqi smear positive pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 663s Year: 2007
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018